Implementation of clinical next-generation sequencing (NGS) of non-small cell lung cancer (NSCLC) to identify EGFR amplification as a potentially targetable oncogenic alteration.
Geoffrey R. Oxnard
Consultant or Advisory Role - Astellas Pharma (U); AstraZeneca; AVEO; Boehringer Ingelheim; Genentech; Novartis
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma
Christine A. Lydon
No relevant relationships to disclose
Neal Ian Lindeman
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
Priyanka R. Shivdasani
No relevant relationships to disclose
Gary Y. Chin
No relevant relationships to disclose
Frank C. Kuo
No relevant relationships to disclose
Bruce E. Johnson
Consultant or Advisory Role - Acceleron Pharma; AstraZeneca; Chugai Pharma; Genentech; KEW Group; Millennium; Pfizer; Teva; Transgenomic; Veridex
Other Remuneration - Genzyme
Pasi A. Janne
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Clovis; Genentech; Merrimack Pharmaceuticals ; Pfizer; Sanofi
Stock Ownership - GATEKEEPER Pharmaceuticals
Other Remuneration - LabCorp
Lynette M. Sholl
No relevant relationships to disclose